

# Judit Marsillach

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3861573/publications.pdf>

Version: 2024-02-01

75  
papers

2,693  
citations

172443

29  
h-index

197805

49  
g-index

81  
all docs

81  
docs citations

81  
times ranked

3170  
citing authors

#	ARTICLE	IF	CITATIONS
1	The paraoxonases: role in human diseases and methodological difficulties in measurement. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2009, 46, 83-106.	6.1	215
2	Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. <i>Free Radical Biology and Medicine</i> , 2008, 45, 146-157.	2.9	162
3	Paraoxonases-1, -2 and -3: What are their functions?. <i>Chemico-Biological Interactions</i> , 2016, 259, 51-62.	4.0	145
4	Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. <i>Toxicology</i> , 2013, 307, 115-122.	4.2	124
5	Human PON1, a biomarker of risk of disease and exposure. <i>Chemico-Biological Interactions</i> , 2010, 187, 355-361.	4.0	98
6	Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. <i>HIV Medicine</i> , 2010, 11, 225-231.	2.2	89
7	Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. <i>BMC Gastroenterology</i> , 2009, 9, 3.	2.0	83
8	Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. <i>Journal of Hepatology</i> , 2006, 45, 51-59.	3.7	82
9	Ancient convergent losses of <i>Paraoxonase 1</i> yield potential risks for modern marine mammals. <i>Science</i> , 2018, 361, 591-594.	12.6	79
10	Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. <i>Atherosclerosis</i> , 2007, 194, 175-181.	0.8	62
11	Increased PAFAH and Oxidized Lipids Are Associated With Inflammation and Atherosclerosis in Hypercholesterolemic Pigs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 2041-2046.	2.4	60
12	Protein adducts as biomarkers of exposure to organophosphorus compounds. <i>Toxicology</i> , 2013, 307, 46-54.	4.2	60
13	The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. <i>Clinical Biochemistry</i> , 2009, 42, 91-98.	1.9	59
14	Biomarkers of organophosphorus (OP) exposures in humans. <i>NeuroToxicology</i> , 2011, 32, 656-660.	3.0	58
15	The results in rodent models of atherosclerosis are not interchangeable. <i>Atherosclerosis</i> , 2007, 195, e85-e92.	0.8	55
16	Serum paraoxonase-1 in chronic alcoholics: Relationship with liver disease. <i>Clinical Biochemistry</i> , 2007, 40, 645-650.	1.9	55
17	Paraoxonase-1 Deficiency Is Associated with Severe Liver Steatosis in Mice Fed a High-fat High-cholesterol Diet: A Metabolomic Approach. <i>Journal of Proteome Research</i> , 2013, 12, 1946-1955.	3.7	54
18	Dietary cholesterol and differential monocyte chemoattractant protein-1 gene expression in aorta and liver of apo E-deficient mice. <i>Biochemical and Biophysical Research Communications</i> , 2006, 340, 1078-1084.	2.1	53

#	ARTICLE	IF	CITATIONS
19	Hepatic monocyte chemoattractant protein-1 is upregulated by dietary cholesterol and contributes to liver steatosis. <i>Cytokine</i> , 2009, 48, 273-279.	3.2	48
20	Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques. <i>European Journal of Clinical Investigation</i> , 2011, 41, 308-314.	3.4	48
21	Paraoxonase-3 Is Depleted from the High-Density Lipoproteins of Autoimmune Disease Patients with Subclinical Atherosclerosis. <i>Journal of Proteome Research</i> , 2015, 14, 2046-2054.	3.7	47
22	Impaired paraoxonase-1 status in obese children. Relationships with insulin resistance and metabolic syndrome. <i>Clinical Biochemistry</i> , 2013, 46, 1830-1836.	1.9	46
23	Measurement of serum paraoxonase-1 activity in the evaluation of liver function. <i>World Journal of Gastroenterology</i> , 2009, 15, 1929.	3.3	45
24	Paraoxonase-1 and Early-Life Environmental Exposures. <i>Annals of Global Health</i> , 2018, 82, 100.	2.0	37
25	Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. <i>Clinica Chimica Acta</i> , 2005, 361, 206-210.	1.1	35
26	Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. <i>Pharmacogenomics</i> , 2013, 14, 1495-1515.	1.3	35
27	Pharmacological and Lifestyle Factors Modulating Serum Paraoxonase-1 Activity. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 911-920.	2.4	32
28	Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. <i>Lipids in Health and Disease</i> , 2010, 9, 46.	3.0	32
29	Human Valacyclovir Hydrolase/Biphenyl Hydrolase-Like Protein Is a Highly Efficient Homocysteine Thiolactonase. <i>PLoS ONE</i> , 2014, 9, e110054.	2.5	31
30	The role of circulating monocyte chemoattractant protein-1 as a marker of hepatic inflammation in patients with chronic liver disease. <i>Clinical Biochemistry</i> , 2005, 38, 1138-1140.	1.9	30
31	Paraoxonase-1 Inhibits Oxidized Low-Density Lipoprotein-Induced Metabolic Alterations and Apoptosis in Endothelial Cells: A Nondirected Metabolomic Study. <i>Mediators of Inflammation</i> , 2013, 2013, 1-9.	3.0	29
32	Deficiency in monocyte chemoattractant protein-1 modifies lipid and glucose metabolism. <i>Experimental and Molecular Pathology</i> , 2007, 83, 361-366.	2.1	26
33	HDL Proteome and Alzheimer's Disease: Evidence of a Link. <i>Antioxidants</i> , 2020, 9, 1224.	5.1	26
34	Evaluating the link between Paraoxonase-1 levels and Alzheimer's disease development. <i>Minerva Medica</i> , 2019, 110, 238-250.	0.9	26
35	ADMINISTRATION OF EXOGENOUS ERYTHROPOIETIN $\hat{2}$ AFFECTS LIPID PEROXIDATION AND SERUM PARAOXONASE ACTIVITY AND CONCENTRATION IN PREDIALYSIS PATIENTS WITH CHRONIC RENAL DISEASE AND ANAEMIA. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2007, 34, 347-349.	1.9	25
36	Connection between the Altered HDL Antioxidant and Anti-Inflammatory Properties and the Risk to Develop Alzheimer's Disease: A Narrative Review. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-13.	4.0	25

#	ARTICLE	IF	CITATIONS
37	Paraoxonase-1 Gene Haplotypes Are Associated with Metabolic Disturbances, Atherosclerosis, and Immunologic Outcome in HIV-1 Infected Patients. <i>Journal of Infectious Diseases</i> , 2010, 201, 627-634.	4.0	24
38	Serum paraoxonase-3 concentration is associated with insulin sensitivity in peripheral artery disease and with inflammation in coronary artery disease. <i>Atherosclerosis</i> , 2012, 220, 545-551.	0.8	24
39	Rare coding variation in paraoxonase-1 is associated with ischemic stroke in the NHLBI Exome Sequencing Project. <i>Journal of Lipid Research</i> , 2014, 55, 1173-1178.	4.2	23
40	Serum Paraoxonase Undergoes Inhibition and Proteolysis During Experimental Acute Pancreatitis. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 891-899.	1.7	22
41	Measurement of serum PON-3 concentration: method evaluation, reference values, and influence of genotypes in a population-based study. <i>Journal of Lipid Research</i> , 2011, 52, 1055-1061.	4.2	21
42	Paraoxonase-1 status in patients with hereditary hemochromatosis. <i>Journal of Lipid Research</i> , 2013, 54, 1484-1492.	4.2	20
43	Developmental expression of paraoxonase 2. <i>Chemico-Biological Interactions</i> , 2016, 259, 168-174.	4.0	19
44	Measurement of serum paraoxonase-1 activity as a potential biomarker for chronic liver impairment. <i>Clinica Chimica Acta</i> , 2007, 386, 114-115.	1.1	18
45	Paraoxonase-1 Is Associated With Corneal Endothelial Cell Alterations in Patients With Chronic Obstructive Pulmonary Disease. , 2013, 54, 5852.		17
46	Interrelationships Between Paraoxonase-1 and Monocyte Chemoattractant Protein-1 in the Regulation of Hepatic Inflammation. <i>Advances in Experimental Medicine and Biology</i> , 2010, 660, 5-18.	1.6	17
47	Metals and Paraoxonases. <i>Advances in Neurobiology</i> , 2017, 18, 85-111.	1.8	17
48	Serum paraoxonase-3 concentration is associated with the severity of hepatic impairment in patients with chronic liver disease. <i>Clinical Biochemistry</i> , 2011, 44, 1320-1324.	1.9	16
49	Longitudinal changes in serum paraoxonase-1 activity throughout normal pregnancy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 880-2.	2.3	15
50	Serum paraoxonase-3 concentration in HIV-infected patients. Evidence for a protective role against oxidation. <i>Journal of Lipid Research</i> , 2012, 53, 168-174.	4.2	15
51	Comparison of Paraoxonase 1 Measurements in Serum and in Lithium-Heparin-Anticoagulated Plasma Samples. <i>Clinical Chemistry</i> , 2005, 51, 922-923.	3.2	14
52	Moderately High Folic Acid Supplementation Exacerbates Experimentally Induced Liver Fibrosis in Rats. <i>Experimental Biology and Medicine</i> , 2008, 233, 38-47.	2.4	14
53	Paraoxonase-1 and -3 Protein Expression in the Brain of the Tg2576 Mouse Model of Alzheimer's Disease. <i>Antioxidants</i> , 2021, 10, 339.	5.1	14
54	Evaluating Gait and Locomotion in Rodents with the CatWalk. <i>Current Protocols</i> , 2021, 1, e220.	2.9	14

#	ARTICLE	IF	CITATIONS
55	Paraoxonase-1 in female infertility: a possible role against oxidative stress-induced inflammation. <i>Fertility and Sterility</i> , 2010, 94, 1132-1134.	1.0	12
56	Proteomic analysis of adducted butyrylcholinesterase for biomonitoring organophosphorus exposures. <i>Chemico-Biological Interactions</i> , 2013, 203, 85-90.	4.0	12
57	Serum paraoxonase-1 activity and genetic polymorphisms: common errors in measurement and interpretation of results. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 893-4.	2.3	11
58	Host-pathogen interactions in the development of metabolic disturbances and atherosclerosis in HIV infection: The role of CCL2 genetic variants. <i>Cytokine</i> , 2010, 51, 251-258.	3.2	11
59	Methodological constraints in interpreting serum paraoxonase-1 activity measurements: an example from a study in HIV-infected patients. <i>Lipids in Health and Disease</i> , 2010, 9, 32.	3.0	11
60	Paraoxonase-1 is only present in traceable amounts in seminal fluid and does not show any relationship with male subfertility. <i>BJU International</i> , 2011, 108, 566-570.	2.5	11
61	Changes in the expression of genes related to apoptosis and fibrosis pathways in CCl4-treated rats. <i>Molecular and Cellular Biochemistry</i> , 2008, 308, 101-109.	3.1	10
62	Paraoxonase-1 Is Not Associated with Coronary Artery Calcification in Type 2 Diabetes: Results from the PREDICT Study. <i>Disease Markers</i> , 2012, 33, 101-112.	1.3	10
63	Paraoxonase-1 (PON-1) Arylesterase Activity Levels in Patients with Coronary Artery Disease: A Meta-Analysis. <i>Disease Markers</i> , 2022, 2022, 1-9.	1.3	10
64	Influence of PON1 Polymorphisms on the Association between Serum Paraoxonase 1 and Homocysteinemia in a General Population. <i>Clinical Chemistry</i> , 2006, 52, 781-782.	3.2	9
65	Paraoxonase-1 is not associated with coronary artery calcification in type 2 diabetes: results from the PREDICT study. <i>Disease Markers</i> , 2012, 33, 101-12.	1.3	8
66	Paraoxonase-1 in Chronic Liver Diseases, Neurological Diseases and HIV Infection. , 2008, , 187-198.		7
67	Serum concentrations of extracellular fatty acid synthase in patients with steatohepatitis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1097-9.	2.3	7
68	Paraoxonase-1 (PON1) Status Analysis Using Non-Organophosphate Substrates. <i>Current Protocols</i> , 2021, 1, e25.	2.9	7
69	Interdisciplinary data science to advance environmental health research and improve birth outcomes. <i>Environmental Research</i> , 2021, 197, 111019.	7.5	6
70	Paraoxonase 2 deficiency in mice alters motor behavior and causes region-specific transcript changes in the brain. <i>Neurotoxicology and Teratology</i> , 2021, 87, 107010.	2.4	5
71	Paraoxonase (PON1), detoxification of nerve agents, and modulation of their toxicity. , 2020, , 1179-1190.		1
72	Paraoxonase-1 and Other HDL Accessory Proteins in Neurological Diseases. <i>Antioxidants</i> , 2021, 10, 454.	5.1	1

#	ARTICLE	IF	CITATIONS
73	Paraoxonase 1 and Postprandial Lipemia. , 2008, , 129-138.		0
74	RELATIONSHIP BETWEEN PARAOXONASE-1 (PON1), MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) AND SUB-CLINICAL ATHEROSCLEROSIS IN HIV-1 INFECTED PATIENTS. Atherosclerosis Supplements, 2008, 9, 261.	1.2	0
75	Pitfalls in measuring high-density lipoprotein cholesterol concentrations in HIV-infected patients. HIV Medicine, 2010, 11, 260-265.	2.2	0